Lipegfilgrastim
Lonquex (lipegfilgrastim) is a protein pharmaceutical. Lipegfilgrastim was first approved as Lonquex on 2013-07-25. It has been approved in Europe to treat neutropenia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| hemic and lymphatic diseases | D006425 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
409 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | D009503 | — | D70 | — | 1 | 3 | — | — | 3 |
| Chemotherapy-induced febrile neutropenia | D064146 | — | — | — | 1 | 2 | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | — | 1 | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | — | — | 1 | — | — | 1 |
| B-cell lymphoma | D016393 | — | — | — | — | 1 | — | — | 1 |
| Aggression | D000374 | EFO_0003015 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoid leukemia | D007945 | — | C91 | 3 | 15 | — | — | — | 15 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 2 | 10 | — | — | — | 10 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | 8 | — | — | — | 8 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 5 | 2 | — | — | 1 | 8 |
| Prostatic neoplasms | D011471 | — | C61 | 4 | 5 | — | — | — | 7 |
| Transitional cell carcinoma | D002295 | — | — | — | 6 | — | — | 1 | 7 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 4 | 4 | — | — | — | 6 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 3 | 4 | — | — | — | 6 |
| Central nervous system neoplasms | D016543 | — | — | 2 | 5 | — | — | — | 6 |
| Head and neck neoplasms | D006258 | — | — | 3 | 3 | — | — | — | 5 |
Show 82 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 16 | — | — | — | 1 | 17 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 2 | — | — | — | 2 | 4 |
| Coronary artery disease | D003324 | — | I25.1 | 1 | — | — | — | 1 | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 1 | — | — | — | 1 | 2 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | — | — | — | — | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 1 | — | — | — | — | 1 |
| Vaccine immunogenicity | D000071497 | — | — | 1 | — | — | — | — | 1 |
Show 13 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pheochromocytoma | D010673 | — | — | — | — | — | — | 2 | 2 |
| Coronary disease | D003327 | — | — | — | — | — | — | 1 | 1 |
| Bone nails | D001858 | — | — | — | — | — | — | 1 | 1 |
| Patient reported outcome measures | D000071066 | — | — | — | — | — | — | 1 | 1 |
| Patient satisfaction | D017060 | — | — | — | — | — | — | 1 | 1 |
| Patient preference | D057240 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lipegfilgrastim |
| INN | lipegfilgrastim |
| Description | Lipegfilgrastim, sold under the brand name Lonquex, is a medication used to reduce the duration of neutropenia and the incidence of febrile neutropenia in adults. It is given by injection under the skin in the abdomen, upper arm or thigh.
|
| Classification | Protein |
| Drug class | colony-stimulating factors: granulocyte colony-stimulating factors (G-CSF); PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1117844-87-7 |
| RxCUI | 1440046 |
| ChEMBL ID | CHEMBL4594230 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB13200 |
| UNII ID | 4AWF0N6QV3 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 171 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
452 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use